$OMER Omeros (NASDAQ: OMER) has finally started to rise and is up over 50% in the past few weeks, but the company seems like it has the “Big Mo” right now. Recently, it showed good trial results for three different compounds that are advancing at a nice pace in its pipeline. In addition, sales of its key approved product “Omidra” are accelerating and are running at a $55 million annual pace right now. The company also addressed its funding overhang successfully, which removes that headwind. Even with the recent rally, the stock sells for just over $13.00 a share. The median price target by the analyst firms that cover the company is north of $40.00 a share, so I could easily see significant upside ahead if the company continues to execute well along its development path and if Omidra sales keep growing.